Moderna Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Moderna şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-0.4%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-0.4%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Moderna: Assessing The Impact Of GSK's Patent Lawsuit

Oct 22

The Market Doesn't Like What It Sees From Moderna, Inc.'s (NASDAQ:MRNA) Revenues Yet As Shares Tumble 28%

Oct 11

Moderna: Still Bullish View

Sep 20

Moderna: Fresh Sell-Off On Cost Cutting Initiatives, Short-Term Outlook Troubling

Sep 12

Moderna's Vaccine Progress Undermined By RSV Market Contraction (Rating Downgrade)

Aug 26

Lacklustre Performance Is Driving Moderna, Inc.'s (NASDAQ:MRNA) 28% Price Drop

Aug 18

Analysts Have Lowered Expectations For Moderna, Inc. (NASDAQ:MRNA) After Its Latest Results

Aug 03

We Discuss Why Moderna, Inc.'s (NASDAQ:MRNA) CEO Compensation May Be Closely Reviewed

Apr 30

Moderna, Inc.'s (NASDAQ:MRNA) Prospects Need A Boost To Lift Shares

Apr 22

Moderna: Considering The Cancer Vaccine Angle

Apr 11

Moderna Continues To Build A Pipeline

Apr 03

Lukewarm Reaction To Moderna's Vaccine Day Sums Up Fine Margins In Play

Mar 27

Moderna, Inc. (NASDAQ:MRNA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Feb 27

Moderna: Counting On Pipeline Too Much

Feb 23

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: MRNA şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: MRNA şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Moderna Piyasaya Karşı Temettü Getirisi

MRNA temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (MRNA)	n/a
Pazarın Alt %25'i (US)	1.3%
Pazarın En İyi %25'i (US)	4.3%
Sektör Ortalaması (Biotechs)	2.1%
Analist tahmini (MRNA) (3 yıla kadar)	0%

Önemli Temettü: MRNA şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, MRNA şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: MRNA şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: MRNA herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Moderna Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Price target decreased by 7.0% to US$85.80

Moderna, Inc. Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Merck and Moderna, Inc. Initiates Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA (Pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients with Certain Types of Non-Small Cell Lung Cancer (NSCLC)

Moderna: Assessing The Impact Of GSK's Patent Lawsuit

Moderna, Inc. to Report Q3, 2024 Results on Nov 07, 2024

The Market Doesn't Like What It Sees From Moderna, Inc.'s (NASDAQ:MRNA) Revenues Yet As Shares Tumble 28%

Moderna, Inc. as Abbas Hussain to Board of Directors

Moderna: Still Bullish View

Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older

Price target decreased by 16% to US$105

Moderna: Fresh Sell-Off On Cost Cutting Initiatives, Short-Term Outlook Troubling

Moderna, Inc. Announces EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1

Moderna, Inc. Receives Medicines and Healthcare Products Regulatory Agency Authorization for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant JN.1

Taiwan Food & Drug Administration Approves Moderna, Inc.'s COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant JN.1

Albertsons Companies, Inc. Offers the Latest Monovalent mRNA COVID Vaccines from Pfizer and Moderna Along with the Annual Flu Vaccine

Moderna's Vaccine Progress Undermined By RSV Market Contraction (Rating Downgrade)

Moderna Receives European Commission Approval for RSV Vaccine Mresvia(R)

Lacklustre Performance Is Driving Moderna, Inc.'s (NASDAQ:MRNA) 28% Price Drop

Gainey McKenna & Egleston Files Class Action Lawsuit Against Moderna Inc

Consensus revenue estimates fall by 21%

Analysts Have Lowered Expectations For Moderna, Inc. (NASDAQ:MRNA) After Its Latest Results

Second quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

New minor risk - Share price stability

Moderna, Inc. Revises Earnings Guidance for the Year 2024

Moderna: State Of Play Ahead Of Q2 Earnings, I'm (Temporarily) Pessimistic

Moderna, Inc. Announces Board Changes

Co-Founder notifies of intention to sell stock

Moderna, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Moderna: Really Strong Competition

Moderna, Inc Announces EMA Committee for Medicinal Products for Human Use

Co-Founder notifies of intention to sell stock

Moment Of Truth Approaches For Moderna's RSV Vaccine

Moderna, Inc. Announces Positive Phase 3 Efficacy Data for mRNA-1283

Moderna, Inc Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19

Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine

What Moderna, Inc.'s (NASDAQ:MRNA) 27% Share Price Gain Is Not Telling You

Moderna & Merck Announces 3-Year Data for mRNA-4157 (V940) in Combination with KEYTRUDA (Pembrolizumab)

Moderna: Betting On Bird Flu Rally Is A Poor Strategy For A Value Investor

Moderna Q1: A Promising Pipeline Is Undervalued

Moderna Announces Update on Investigational Rsv Vaccine

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

We Discuss Why Moderna, Inc.'s (NASDAQ:MRNA) CEO Compensation May Be Closely Reviewed

Moderna, Inc.'s (NASDAQ:MRNA) Prospects Need A Boost To Lift Shares

Moderna, Inc. to Report Q1, 2024 Results on May 02, 2024

Moderna: Considering The Cancer Vaccine Angle

Arbutus Biopharma Announces Claim Construction Ruling in Its Ongoing Patent Infringement Lawsuit Against Moderna

Moderna Continues To Build A Pipeline

Insufficient new directors

Moderna, Inc. Advances Multiple Vaccine Programs to Late-Stage Clinical Trials

Lukewarm Reaction To Moderna's Vaccine Day Sums Up Fine Margins In Play

Moderna, Inc. Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine

Co-Founder notifies of intention to sell stock

Moderna, Inc. (NASDAQ:MRNA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

President notifies of intention to sell stock

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Moderna: Counting On Pipeline Too Much

Moderna, Inc., Annual General Meeting, May 06, 2024

Consensus EPS estimates fall by 12%

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin